Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 16;12(6):976.
doi: 10.3390/jpm12060976.

Biological Therapy of Severe Asthma and Nasal Polyps

Agamemnon Bakakos  1 , Florence Schleich  2 , Petros Bakakos  1
Affiliations
Review

Biological Therapy of Severe Asthma and Nasal Polyps

Agamemnon Bakakos et al. J Pers Med. .

Abstract

Chronic rhinosinusitis is a common disease worldwide and can be categorized into chronic rhinosinusitis with nasal polyps and chronic rhinosinusitis without nasal polyps. Chronic rhinosinusitis with nasal polyps is common in patients with asthma and, particularly, severe asthma. Severe asthma is effectively treated with biologics and the coexistence of severe asthma with chronic rhinosinusitis with nasal polyps presents a phenotype that is more likely to respond to such treatment. In this review, we focus on the link between asthma and nasal polyps, and we review the treatment effect of various monoclonal antibodies in patients with severe asthma and nasal polyps as well as in patients with nasal polyps without asthma or with mild-to-moderate asthma. With the enhancement of our armamentarium with new monoclonal antibodies the right choice of biologic becomes an important target and one that is difficult to achieve due to the lack of comparative head-to-head studies.

Keywords: asthma; benralizumab; chronic rhinosinusitis with nasal polyps (CRSwNP); dupilumab; mepolizumab; monoclonal antibodies.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Hastan D., Fokkens W.J., Bachert C., Newson R.B., Bislimovska J., Bockelbrink A., Bousquet P.J., Brozek G., Bruno A., Dahlen S.E., et al. Chronic rhinosinusitis in Europe—An underestimated disease. A GA2LEN study. Allergy. 2011;66:1216–1223. doi: 10.1111/j.1398-9995.2011.02646.x. - DOI - PubMed
    1. Bachert C., Zhang L., Gevaert P. Current and future treatment options for adult chronic rhinosinusitis: Focus on nasal polyposis. J. Allergy Clin. Immunol. 2015;136:1431–1440. doi: 10.1016/j.jaci.2015.10.010. - DOI - PubMed
    1. Fokkens W.J., Lund V.J., Mullol J., Bachert C., Alobid I., Baroody F., Cohen N., Cervin A., Douglas R., Gevaert P., et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50:1–12. doi: 10.4193/Rhino12.000. - DOI - PubMed
    1. Alobid I., Benitez P., Bernal-Sprekelsen M., Roca J., Alonso J., Picado C., Mullol J. Nasal polyposis and its impact on quality of life: Comparison between the effects of medical and surgical treatments. Allergy. 2005;60:452–458. doi: 10.1111/j.1398-9995.2005.00725.x. - DOI - PubMed
    1. Hakansson K., Bachert C., Konge L., Thomsen S.F., Pedersen A.E., Poulsen S.S., Martin-Bertelsen T., Winther O., Backer V., von Buchwald C. Airway Inflammation in Chronic Rhinosinusitis with Nasal Polyps and Asthma: The United Airways Concept Further Supported. PLoS ONE. 2015;10:e0127228. doi: 10.1371/journal.pone.0127228. - DOI - PMC - PubMed

LinkOut - more resources